<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article         dtd-version="1.4">
            <front>

                <journal-meta>
                                    <journal-id></journal-id>
            <journal-title-group>
                                                                                    <journal-title>Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi</journal-title>
            </journal-title-group>
                            <issn pub-type="ppub">1012-2354</issn>
                                                                                                        <publisher>
                    <publisher-name>Erciyes Üniversitesi</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id/>
                                                                                                                                                                                            <title-group>
                                                                                                                        <article-title>Cancer immunotherapy</article-title>
                                                                                                                                                                                                <trans-title-group xml:lang="tr">
                                    <trans-title>Kanser immünoterapisi</trans-title>
                                </trans-title-group>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                <name>
                                    <surname>Barbaros</surname>
                                    <given-names>Mustafa Burak</given-names>
                                </name>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Dikmen</surname>
                                    <given-names>Miriş</given-names>
                                </name>
                                                                    <aff>Anadolu Üniversitesi, Eczacılık Fakültesi, Farmakoloji Anabilim Dalı, Eskişehir, Türkiye</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20150801">
                    <day>08</day>
                    <month>01</month>
                    <year>2015</year>
                </pub-date>
                                        <volume>31</volume>
                                        <issue>4</issue>
                                        <fpage>177</fpage>
                                        <lpage>182</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20150801">
                        <day>08</day>
                        <month>01</month>
                        <year>2015</year>
                    </date>
                                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 1985, Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi</copyright-statement>
                    <copyright-year>1985</copyright-year>
                    <copyright-holder>Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi</copyright-holder>
                </permissions>
            
                                                                                                <abstract><p>As one of the spesific methods in cancer treatment, immunotherapy means to treat some diseases such as canncer by using one’s particular parts of immune system. Due to its ability to prevent damage to healthy cells by directly targeting cancer cells, it attracts more attention everyday. In immunotherapy, it’s possible to create immune response by stimulating body’s own cells or with externally supplied substances. From the second half of the 19th century till today, various immunotherapy methods found themselves a place in practice. Through better understandng of the mechanisms of development, prevention and elimination of cancer, advances in all immunotherapeutic methods also take place. Today, monoclonal antbodies, adoptive immunotherapy, vaccines, cytokines and immune system supporting treatmens are developed and applied aganist cancer in this context. In the light of current literature, this study reviews information about cancer immunotherapy.</p></abstract>
                                                                                                                                    <trans-abstract xml:lang="tr">
                            <p>Kanser tedavisinde spesifik yöntemlerden biri olan immünoterapi, bireyin bağışıklık sisteminin belirli kısımlarını kullanarak kanser gibi çeşitli hastalıkları tedavi etmek anlamına gelir. Doğrudan kanser hücrelerini hedef alarak sağlıklı hücrelere zarar vermemesiyle immünoterapiye olan ilgi her geçen gün artmaktadır. İmmünoterapide vücüdun kendi hücreleri stimüle edilerek ya da dışarıdan verilen maddelerle immün yanıt oluşturulabilir. 19. Yüzyılın ikinci yarısından günümüze kadar kansere karşı çeşitli immünoterapi yöntemleri, uygulamada kendine yer bulmuştur. Kanserin oluşumu, engellenmesi ve elimine edilmesine yönelik mekanizmaların daha iyi anlaşılmasıyla birlikte tüm immünoterapötik yöntemlerde de gelişmeler yaşanmaktadır. Günümüzde monoklonal antikorlar, adoptif immünoterapi, aşılar, sitokinler ve immün sistemi destekleyici tedaviler bu kapsamda geliştirilmekte ve kansere karşı uygulanmaktadır. Bu çalışmada, güncel literatür bilgileri de göz önünde bulundurularak, kanser immünoterapisine dair bilgiler derlenmiştir.</p></trans-abstract>
                                                            
            
                                                            <kwd-group>
                                                    <kwd>Cancer</kwd>
                                                    <kwd>   İmmunotherapy</kwd>
                                                    <kwd>   monoclonal antibody</kwd>
                                                    <kwd>   adoptive immunotherapy</kwd>
                                                    <kwd>   vaccine</kwd>
                                                    <kwd>   cytokine</kwd>
                                            </kwd-group>
                                                        
                                                                            <kwd-group xml:lang="tr">
                                                    <kwd>Kanser</kwd>
                                                    <kwd>   immünoterapi</kwd>
                                                    <kwd>   monoklonal antikor</kwd>
                                                    <kwd>   adoptif immunoterapi</kwd>
                                                    <kwd>   aşı</kwd>
                                                    <kwd>   sitokin</kwd>
                                            </kwd-group>
                                                                                                            </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">American Cancer Societya, Cancer Immunotherapy, Copyright tarihi:24.05.2015 Cancer Society. Erişim</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">Zhou J., Advances and Prospects in Cancer Immunotherapy, New Journal of Science, 2014, 1-13, 2014.</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">Wayteck L., Breckpot K., Demeester J., De Smedt S. C., Raemdonck K., A Personalized View on Cancer Immunotherapy, Cancer Letters, 352(2014), 113-125, 2013.</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">Aslan G., Tümör İmmünolojisi, Turk. J. Immunol., 15(1), 7- 13, 2010.</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">Curiel T. J., Cancer Immunotherapy: Paradigms, Practice and Promise, s. 5, Springer Science+Business Media, New York, 2013.</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">Eskander R. M., Tewari K. S., Immunotherapy: An Evolving Paradigm in the Treatment of Advanced Cervical Cancer, Clinical Therapeutics, 37(1), 20-38, 2015.</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">Parish C. R., Cancer Immunotherapy: The Past, the Present and the Future, Immunology and Cell Biology, 81, 106-113, 2003.</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">Waldmann T., Immunotherapy: Past, Present and Future, Nature Medicine, 9(3), 269-277, 2003.</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">Han J., Monoclonal Antibodies as Cancer Therapeutics, N.A.J.Med Sci.,3(3), 146-151, 2010.</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">Kim R., Emi M., Tanabe K., Cancer Immunoediting from Immune surveillance to Immune Escape, Immunology, 121, 1-14, 2007.</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">Kırmaz C., Özentürk Ö., Malignitelere Karşı Gelişen İmmün Yanıt, Astım Allerji İmmünoloji, 2(3), 167-174, 2004.</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">Chimal-Ramirez G. K., Espinoza-Sanchez N. A., Fuentes- Panana E. M., Protumor Activities of the Immune Response: Insights in the Mechanisms of Immunological Shift, Oncotraining and Oncopromotion, Journal of Oncology, 2013, 1-16, 2013.</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">Dunn G. P., Old L. J., Schreiber R. D., The Immunobiology of Cancer Immunosurveillance and Immunoediting, Immunity, 21, 137-148, 2004.</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">Demirelli F. H., Hedefe Yönelik Kanser Tedavisi ve Monoklonal Antikorlar,” ANKEM Derg., 19(Suppl 2), 123- 125, 2005.</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">Şakalar Ç., İzgi K., Canatan H., Kanser İmmün Terapi ve Monoklonal Antikorlar, F. Ü. Sağ. Bil. Tıp Derg., 27(2), 105-110, 2013.</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">Özet G., Baykal Y., Özet A., Alanoğlu G., Adoptif İmmünoterapi, T. Klin. Tıp Bilimleri, 16(5), 329-332, 1996.</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">Harris T. J., Drake C. G., Primer on Tumor Immunology and Cancer Immunotherapy, Journal for ImmunoTherapy of Cancer, 1(12), 1-9, 2013.</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
